Please provide your email address to receive an email when new articles are posted on . Researchers evaluated the risk of adverse outcomes in older patients across categories of eGFR. The database ...
Second-Line Chemotherapy With Irinotecan Plus Carmustine in Glioblastoma Recurrent or Progressive After First-Line Temozolomide Chemotherapy: A Phase II Study of the Gruppo Italiano Cooperativo di ...
Black Diamond Therapeutics, Inc. is developing a next-generation EGFR inhibitor with promising early data in lung cancer. BDTX-1535 targets EGFR mutations, especially resistance drivers, with key data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback